Search for content, post, videos

Half of the patients dosed in Guard Therapeutics’ AKITA study

Guard Therapeutics have announced that 134 of the planned 268 patients have been dosed in the global randomized, double-blinded and placebo-controlled Phase 2 clinical trial (AKITA). The AKITA study has been designed to evaluate the kidney-protective effects of the investigational drug RMC-035 in
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.